CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Perrigo Starting Shipments of Guaifenesin Extended-Release 600mg

View Comments
perrigo
(credit: istock) Technology Report
Read More

ALLEGAN — Perrigo Co. (Nasdaq: PRGO) Monday announced that it has begun shipments of Guaifenesin 600mg Extended-Release tablets in a launch to its retail and wholesale customers.

This major new product is the first product that is generically equivalent to Mucinex 600mg Extended Release tablets. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

Mucinex 600mg Extended-Release tablets (Guaifenesin 600mg Extended-Release Tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $135 million through food, drug and mass merchandisers for the last 12 months.

“This launch is representative of the Perrigo team’s abilities to overcome challenging circumstances as evidenced by this product’s complex formulation and patent challenges,” said Perrigo chairman and CEO Joseph C. Papa. “The team worked diligently to formulate the product, prove the product’s non-infringement to existing patents, validate and achieve commercial production, and bring the product to market. Perrigo’s achievement represents the first store brand equivalent to be approved by the U.S. Food and Drug Administration and marketed to consumers as a high quality store brand product that will represent considerable savings when compared to the national brand. This is another excellent example of Perrigo’s investment and commitment to making quality healthcare more affordable for our customers.”  

From its beginnings as a packager of generic home remedies in 1887, Allegan-based Perrigo has grown to become a leading global provider of over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, pet health, dietary supplements and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia.

More at www.perrigo.com.

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 1,885 other followers